← Russell 3000 cross-section

MEDP Medpace Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-23, not restated
Healthcare

Scale

Market cap
$17.3bn
Revenue TTM
$2.8bn
Net income TTM
$492m
Free cash flow
$707m
Composite score
63.7
Sector rank
#501

Valuation

P / E
35.1
EV / EBITDA
27.4
EV / sales
6.0
FCF yield
4.09%
Earnings yield vs 10-yr
-1.88pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.7%
EBITDA margin
22.0%
ROE
113.3%
ROIC
Revenue growth
24.7%

Insider activity, last 90 days

Net open-market
$-89.57m
Buyers
0
Sellers
8

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Changes in revenue from period to period are driven primarily by new business volume and task order execution activity, project cancellations, and the mix of active studies during a given period that can vary based on therapeutic area and or study life cycle stage. Total direct costs, as a percentage of net revenue, can vary from period to period due to project labor efficiencies, changes in workforce, compensation/bonus programs and service mix. As of June 30, 2026, our backlog increased by $140.6 million, or 4.9%, to $3,014.2 million compared to $2,873.6 million as of June 30, 2025. We have translated the Euro into U.S. …Medpace Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-23

Read the full passage →